文献速递乳腺癌

18F-FES PET-CT评估乳腺癌复发或转移灶雌激素受体状态的诊断准确性与安全性:前瞻性队列研究

Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
PubMed 文献 · Lancet Oncol · 2019-03-04

在韩国首尔峨山医学中心开展前瞻性队列研究,纳入93例首次复发或转移的乳腺癌患者,评估18F-FES PET-CT与免疫组化检测雌激素受体状态的一致性。85例可分析患者中,阳性状态一致率为76.6%(95%CI 62.0-87.7),阴性状态一致率为100.0%(90.8-100.0)。最常见不良事件为操作相关疼痛,9例(10%)发生,无严重不良事件。

要点

  • 18F-FES PET-CT与免疫组化检测雌激素受体状态的阴性一致率达100.0%(95%CI 90.8-100.0)。
  • 阳性一致率为76.6%(95%CI 62.0-87.7),雌激素受体阳性且PET阳性者孕激素受体表达更高(23/34 vs 0/11,p<0.0001)。
  • 最常见不良事件为操作相关疼痛,9例(10%)发生,无严重不良事件。

核心结论

  • 在本队列中,18F-FES PET-CT与免疫组化检测雌激素受体状态的阴性一致率高,提示复发或转移性雌激素受体阳性乳腺癌病灶的18F-FES阳性摄取可能作为雌激素受体检测的替代方法。
  • 当重新检测雌激素受体状态不可行时,分期评估应包括18F-FES PET-CT。

研究设计与样本

  • 前瞻性队列研究,在韩国首尔峨山医学中心开展。
  • 纳入标准:乳腺癌、首次复发或转移、年龄≥19岁、ECOG体能状态评分0-2。
  • 主要目标:显示定性18F-FES PET-CT判读与免疫组化检测雌激素受体表达结果之间的一致性,免疫组化作为非参考标准检测。
  • 18F-FES PET-CT:静脉注射111-222 MBq的18F-FES后行全身显像,剂量主要根据辐射剂量学分析确定;高于背景强度的18F-FES摄取判读为阳性。
  • 疗效分析纳入所有经组织学确诊的复发或转移性乳腺癌患者,且接受18F-FES并具有可用PET-CT图像(意向诊断分析);安全性分析纳入所有接受18F-FES的患者。

主要发现

  • 2013年11月27日至2016年11月10日共入组93例患者;疗效分析纳入85例,其中雌激素受体阳性47例(55%),雌激素受体阴性38例(45%)。
  • 18F-FES PET-CT与免疫组化检测雌激素受体状态的阳性状态一致率为76.6%(95%CI 62.0-87.7),阴性状态一致率为100.0%(95%CI 90.8-100.0)。
  • 雌激素受体阳性且18F-FES PET-CT阳性的患者孕激素受体表达显著高于雌激素受体阳性且18F-FES PET-CT阴性的患者(23/34例[68%] vs 0/11例;p<0.0001)。
  • 接受18F-FES注射的90例患者中,最常见不良事件为操作相关疼痛9例(10%);除1例(1%)注射部位疼痛外,无不良事件与研究药物相关;未记录到严重不良事件。

关键数值与推荐

  • 阳性状态一致率:76.6%(95%CI 62.0-87.7)。
  • 阴性状态一致率:100.0%(95%CI 90.8-100.0)。
  • 孕激素受体表达:雌激素受体阳性且18F-FES PET-CT阳性组23/34例(68%) vs 雌激素受体阳性且18F-FES PET-CT阴性组0/11例;p<0.0001。
  • 不良事件:操作相关疼痛9/90例(10%);注射部位疼痛1/90例(1%);无严重不良事件。

临床怎么用

  • 作者认为,复发或转移性雌激素受体阳性乳腺癌病灶的18F-FES阳性摄取可能作为该情境下雌激素受体检测的替代方法。
  • 作者建议,当重新检测雌激素受体状态不可行时,分期评估应包括18F-FES PET-CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A biopsy of first recurrence or metastatic disease is recommended to re-evaluate oestrogen receptor status in patients with breast cancer and to select appropriate treatment. However, retesting for oestrogen receptor status with rebiopsy is not always feasible, depending on lesion location and the risk associated with biopsy, and in these cases clinicians continue to treat patients according to the oestrogen receptor status of the primary tumour. Consequently suboptimal therapy might be offered to these patients. We assessed the diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol (18F-FES) PET-CT to assess oestrogen receptor status in patients with recurrent or metastatic breast cancer. METHODS: We did a prospective cohort study at the Asan Medical Center, Seoul, South Korea. Eligible patients had breast cancer, with first recurrence or metastatic disease at presentation, were 19 years or older, and had an Eastern Cooperative Oncology Group performance status of 0-2. The primary objective was to show the agreement between qualitative 18F-FES PET-CT interpretation and the results of oestrogen receptor expression by immunohistochemical assay, a non-reference standard test. Whole-body 18F-FES PET-CT imaging was done after intravenous injection of 111-222 MBq of 18F-FES, with dosing primarily determined by radiation dosimetry analysis. 18F-FES uptake above background intensity was interpreted as positive. Efficacy was assessed in all patients with histologically confirmed recurrent or metastatic breast cancer who received 18F-FES and had PET-CT images available (intention-to-diagnose analysis), and safety was assessed in all patients who received 18F-FES. This study is registered with ClinicalTrials.gov, number NCT01986569. FINDINGS: Between Nov 27, 2013, and Nov 10, 2016, 93 patients were enrolled. Of the 85 patients included in the efficacy analysis, 47 (55%) were oestrogen receptor-positive and 38 (45%) were oestrogen receptor-negative. Positive status percent agreement between the 18F-FES PET-CT results and oestrogen receptor status by immunohistochemical assay was 76·6% (95% CI 62·0-87·7) and the negative status percent agreement was 100·0% (90·8-100·0). Patients who were oestrogen receptor-positive and had a positive 18F-FES PET-CT result had a significantly higher progesterone receptor expression than those who were oestrogen receptor-positive and had a negative 18F-FES PET-CT result (23 [68%] of 34 patients vs 0 of 11 patients; p<0·0001). The most common adverse event was procedural pain in nine (10%) of 90 patients injected with 18F-FES. No adverse events were related to the study drug except injection site pain in one (1%) patient. No serious adverse events were recorded. INTERPRETATION: The high negative percent agreement between 18F-FES PET-CT and oestrogen receptor status by immunohistochemical assay in this cohort suggests that positive 18F-FES uptake by recurrent or metastatic oestrogen receptor-positive breast cancer lesions could be an alternative to oestrogen receptor assays in this setting. Staging assessment should include 18F-FES PET-CT when retesting oestrogen receptor status is not feasible. FUNDING: Asan Institute for Life Sciences, Ministry of Health and Welfare, South Korea.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Chae SY, Ahn SH, Kim SB, et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019. PMID: 30846327. doi:10.1016/S1470-2045(18)30936-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。